Blueprint Medicines (BPMC) Insider Trading & Ownership $101.51 -1.49 (-1.45%) Closing price 04:00 PM EasternExtended Trading$101.56 +0.05 (+0.04%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Blueprint Medicines (NASDAQ:BPMC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.21%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)9Amount OfInsider Selling(Last 12 Months)$23.96 M Get BPMC Insider Trade Alerts Want to know when executives and insiders are buying or selling Blueprint Medicines stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BPMC Insider Buying and Selling by Quarter Blueprint Medicines Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/5/2025Ariel HurleyInsiderSell2,752$103.13$283,813.76 5/5/2025Christina RossiCOOSell2,274$101.75$231,379.50 3/24/2025Christina RossiCOOSell2,274$95.02$216,075.48 3/3/2025Ariel HurleyInsiderSell3,203$92.62$296,661.86 1/21/2025Christina RossiCOOSell2,274$110.14$250,458.36 1/21/2025Jeffrey W AlbersDirectorSell15,161$109.53$1,660,584.33 1/21/2025Kate HavilandCEOSell1,446$110.24$159,407.04 1/13/2025Ariel HurleyInsiderSell2,250$100.00$225,000.00 1/13/2025Jeffrey W AlbersDirectorSell5,000$102.28$511,400.00 12/19/2024Jeffrey W AlbersDirectorSell15,000$89.77$1,346,550.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/18/2024Christina RossiCOOSell2,274$95.91$218,099.34 12/12/2024Ariel HurleyInsiderSell1,819$93.26$169,639.94 11/29/2024Kate HavilandCEOSell2,353$96.60$227,299.80 11/27/2024Christina RossiCOOSell2,274$95.10$216,257.40 10/3/2024Fouad NamouniInsiderSell3,633$89.32$324,499.56 8/5/2024Philina LeeInsiderSell41,913$93.19$3,905,872.47 7/5/2024Debra Durso-BumpusInsiderSell3,850$111.20$428,120.00 7/3/2024Debra Durso-BumpusInsiderSell8,817$111.29$981,243.93 6/28/2024Debra Durso-BumpusInsiderSell333$111.15$37,012.95 6/21/2024Debra Durso-BumpusInsiderSell74,034$104.19$7,713,602.46 6/5/2024Percy H CarterInsiderSell4,000$105.13$420,520.00 6/3/2024L. Becker HewesInsiderSell4,922$106.43$523,848.46 5/31/2024L. Becker HewesInsiderSell34,108$105.91$3,612,378.28 (Data available from 1/1/2013 forward) BPMC Insider Trading Activity - Frequently Asked Questions Who is on Blueprint Medicines's Insider Roster? The list of insiders at Blueprint Medicines includes Ariel Hurley, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, Jeffrey W Albers, Kate Haviland, L. Becker Hewes, Michael Landsittel, Percy H Carter, Philina Lee, and Tracey L Mccain. Learn more on insiders at BPMC. What percentage of Blueprint Medicines stock is owned by insiders? 4.21% of Blueprint Medicines stock is owned by insiders. Learn more on BPMC's insider holdings. Which Blueprint Medicines insiders have been selling company stock? The following insiders have sold BPMC shares in the last 24 months: Ariel Hurley ($1,229,891.48), Christina Rossi ($1,682,758.38), Christopher K Murray ($1,009,854.65), Debra Durso-Bumpus ($9,159,979.34), Fouad Namouni ($505,637.70), Jeffrey W Albers ($11,290,541.87), Kate Haviland ($1,517,067.00), L. Becker Hewes ($4,417,093.67), Michael Landsittel ($3,184,292.59), Percy H Carter ($540,622.42), Philina Lee ($3,905,872.47), and Tracey L Mccain ($471,043.86). How much insider selling is happening at Blueprint Medicines? Insiders have sold a total of 420,341 Blueprint Medicines shares in the last 24 months for a total of $38,914,655.43 sold. Blueprint Medicines Key ExecutivesMs. Kathryn Haviland (Age 48)President, CEO & Director Compensation: $1.17M2 recent tradesMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Director Compensation: $50kMr. Michael Landsittel (Age 52)Chief Financial Officer Compensation: $785.36kMs. Tracey L. McCain Esq. (Age 56)Executive VP, Chief Legal & Compliance Officer and Secretary Compensation: $764.9kDr. Fouad Namouni M.D. (Age 55)President of Research & Development Compensation: $916.4kMs. Ariel Hurley (Age 50)Senior VP, Finance & Principal Accounting Officer 4 recent tradesDr. Christopher K. Murray Ph.D. (Age 60)Senior VP of Technical Operations and Chief Technical Operations & Quality Officer Compensation: $338.37kDr. Percy H. Carter M.B.A. (Age 53)Ph.D., Chief Scientific Officer Compensation: $761.15kJenna CohenSenior Director & Head of Investor RelationsMs. Debra Durso-Bumpus (Age 54)Chief People Officer More Insider Trading Tools from MarketBeat Related Companies BNTX Insider Trading ONC Insider Trading TEVA Insider Trading SMMT Insider Trading ITCI Insider Trading GMAB Insider Trading VTRS Insider Trading MRNA Insider Trading ROIV Insider Trading RVMD Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Sprouts Stock: Insider Sales, But Strong Bullish Signals5 Hot Small-Cap Insiders Bought at the Peak of Tariff FearsThe Top-Ranked Insider Buys From April by Market CapMcDonald’s Insiders Sell Shares! Investors Should Do the Opposite This page (NASDAQ:BPMC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
